Artiva Biotherapeutics, Inc. ARTV
Set alert
At close · Nov 2
After hours · Nov 2, 4:05 PM ET
- YTD
- -2.33%
- 1 year
- +0.48%
- Open
- 4.21
- Prev close
- 4.19
- Mkt cap
- 204.85M
- Vol
- 938.35K
- Avg vol
- 628.91K
- EPS
- -3.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.15
- High
- 4.22
- Forward P/E
- -3.18
- Beta
- 0.00
- Short ratio
- 20.47
- Inst. own
- 89.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 11.60
- 200-d avg
- 11.88
- 1y target
- 21.25
News
3 days ago benzinga.com
Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies
Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
6 days ago benzinga.com
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Artiva Biotherapeutics Inc. (NASDAQ:ARTV) announced it will halt further clinical development of its lead cell therapy candidate, slash roughly 94% of its workforce, and evaluate strategic…
6 days ago benzinga.com
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
6 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
6 days ago benzinga.com
Crude Oil Moves Lower; Corning Earnings Top Views
U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
-
6 days ago benzinga.com
Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4
Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.
6 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
-
6 days ago benzinga.com
Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation
Clinical Development Discontinuation and Patient Follow-UpUpdated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion…
-
6 days ago benzinga.com
Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development
Strategic Alternatives and Corporate RestructuringArtiva’s Board of Directors is evaluating internal options and potential strategic alternatives intended to maximize stockholder value. Leerink…
-
6 days ago benzinga.com
Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
6 days ago globenewswire.com
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
1 week ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
1 month ago globenewswire.com
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with…
-
1 month ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.
-
1 month ago benzinga.com
Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients…
1 month ago globenewswire.com
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
1 month ago globenewswire.com
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
1 month ago globenewswire.com
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
1 month ago globenewswire.com
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase…
2 months ago benzinga.com
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
2 months ago globenewswire.com
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
2 months ago defenseworld.net
2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC
5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) in the second quarter, according to the company in its most recent 13F filing with the SEC.…
2 months ago defenseworld.net
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
2 months ago globenewswire.com
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive…
3 months ago globenewswire.com
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…
3 months ago zacks.com
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
4 months ago globenewswire.com
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…
4 months ago benzinga.com
Why Cracker Barrel Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 results and raising FY26 sales guidance.
-
4 months ago benzinga.com
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.
-
4 months ago benzinga.com
Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
4 months ago globenewswire.com
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic…
5 months ago prnewswire.com
The $13 Million Company Teaching the Immune System to Hunt Cancer
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
5 months ago globenewswire.com
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…
-
5 months ago benzinga.com
Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T…
5 months ago globenewswire.com
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
5 months ago globenewswire.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple…
-
5 months ago benzinga.com
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41
Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.
-
5 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40
Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40
Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.
5 months ago seekingalpha.com
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.
5 months ago benzinga.com
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
5 months ago benzinga.com
Market-Moving News for May 8th
RKLB: 8% | Rocket Lab shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance above estimates. The company announced it will acquire…
-
5 months ago benzinga.com
Artiva Biotherapeutics Suspends Share Offering Under Sales Agreement With Leerink Partners
On May 8, 2026, the Company delivered written notice to Leerink Partners LLC ("Leerink") that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus…
-
5 months ago benzinga.com
Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.89) by 6.74 percent. This is a 14.46 percent decrease over…
-
6 months ago benzinga.com
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting lower-than-expected earnings and sales.